Conceptualizando VII: Papel de la glucosa y la 18F-FDG en tumores malignos, con enfoque en cáncer de tiroides (Parte I)


  1. Nagataki S, Nystrom E. Epidemiology and primary prevention of thyroid cancer. Thyroid. 2002;12:889-896.
  2. Carling T, Udelsman R: Thyroid tumors. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Cancer: Principles and Practice of Oncology. Vols. 1 & 2. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2008, pp 1663-82. 

  3. Pacini F, Vorontsova T, Molinaro E, et al.: Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout. Lancet 352 (9130): 763-6, 1998.
  4. Tronko MD, Howe GR, Bogdanova TI, et al.: A cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: thyroid cancer in Ukraine detected during first screening. J Natl Cancer Inst 98 (13): 897-903, 2006.
  5. Iribarren C, Haselkorn T, Tekawa IS, et al.: Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer 93 (5): 745-50, 2001.
  6. Ferrer García JC, Merino Torres JF, Ponce Marco JL, Piñón Sellés F. Metástasis poco habituales del carcinoma diferenciado de tiroides. An Med Interna (Madrid) 2002; 19: 579-582.
  7. Cano Valdez, Aspectos Histológicos del Cáncer Diferenciado de la Tiroides. Cancerología 4 (2009): 73-83
  8. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10-year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70:511–518.
  9. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999; 9:421-427.
  10. Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg 1996;172:692-4.
  11. Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 1998; 138:249-252.
  12. Duren, M., Siperstein, A.E., Shen, W., Duh, Q.Y., Morita, E., Clark, O.H.: Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery 126:13, 1999
  13. Lind P, Kumnig M, Heinisch I, Mikosch P, Gallwitsch ... Iodine supplementation in Austria: methods and results.Thyroid 2002;12:903-907
  14. Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endo- crinol Metab Clin North Am. 1996;25:93-113.
  15. Lubin E, Mechlis-Frish S, Zatz S, Shimoni A, Segal K, Avra- ham A, et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metasta- tic differentiated thyroid carcinoma. J Nucl Med. 1994;35:257- 62.
  16. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997;7:613-619
  17. Hard G. C. Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. Environ. Health Perspect., 106: 427-436, 1998
  18. Williams ED. Mechanisms and pathogenesis of thyroid cancer in animals and man. Mutation Res. 1995;333:123–129.
  19. Merck Manual of Medical Information website. Available at: . Accessed March 25, 2003. Consultado 2011
  20. Defining cancer. National Cancer Institute website. Available at: . Accessed August 1, 2008. Consultado 2011.
  21. Detailed guide. American Cancer Society website. Available at: . Accessed August 1, 2008. Consultado 2011.
  22. Fuster V, Ross R, Topol EJ. Aterosclerosis y enfermedad arterial coronaria. Springer Science & Business, 1997, pp. 434.
  23. Darmell J. Lodish H, Baltimore D. Molecular cell biology. New York: Freeman; 1986:987-1035.
  24. Robbins y Cotran Patología estructural y funcional compendio 7a ediion, Elsevier, 2007. Pág. 170, 180.
  25. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Par- mentier C. Detection and treatment of lung metastases of diffe- rentiated thyroid carcinoma in patients with normal chest x- rays. J Nucl Med. 1988;29:1790-4.
  26. Black EG, Cassoni A, Gimlette TM, Harmer CL, Maisey MN, Oates GD, et al. Serum thyroglobulin in thyroid cancer. Lancet. 1981;2:443-5.
  27. Grant S, Luttrell B, Reeve T, Wiseman J, Wilmshurst E, Stiel J, et al. Thyroglobulin may be undetectable in the serum of pa- tients with metastatic disease secondary to differentiated thy- roid carcinoma. Follow-up of differentiated thyroid carcinoma. Cancer. 1984;54:1625-8.
  28. Hamburger JI, Miler JM, Kini SR. Lymphoma of the thyroid. Ann Intern Med 1993; 99:685-693.
  29. Rosai J, Carcangiu ML, Delellis RA. Tumors of the thyroid gland. In: Rosai J, Sobin LH, eds. Atlas of Tumor Pathol- ogy. Vol 5. Washington, DC: Armed Forces Institute of Pa- thology; 1992:161–182.
  30. Rosai J. Poorly differentiated carcinomas of the thyroid: introduction to the issue, its landmarks, and clinical impact. Endocr Pathol. 2004;15:293–296.
  31. Xavier Matias-Guiu, José Cameselle-Teijeiro Clasificación de la OMS de cáncer de tiroides (2004)
  32. Akslen LA, Livolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyr- oid carcinoma. Cancer. 2000;88:1902–1908.
  33. Sakamoto A. Definition of poorly differentiated carcinoma of the thyroid: the Japanese experience. Endocr Pathol. 2004;15:307–311.
  34. Lazar V, Bidart JM, Caillou B, y col. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab. 1999 Sep;84(9):3228-34
  35. Schönberger J, Rüschoff J, Grimm D, y col.Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid. 2002 Sep;12(9):747-54.
  36. Matsuzu K, Segade F, Matsuzu U, y col.. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid. 2004 Oct;14(10):806-12
  37. Hooft L, van der Veldt AA, van Diest PJ, y col. [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. J Clin Endocrinol Metab. 2005 Jan;90(1):328-34
  38. Matsuzu K, Segade F, Wong M, y col.. Glucose transporters in the thyroid. Thyroid. 2005 Jun;15(6):545-50
  39. Maier A, T Asano, Volker A, E Boles, Fuhrmann GF (2002). "Caracterización del transporte de glucosa en Saccharomyces cerevisiae con vesículas de membrana plasmática (contratransporte) y células intactas (la captación inicial) con un solo Hxt1, Hxt2, Hxt3, Hxt4, Hxt6, Hxt7 o GAL2 transportistas" La investigación FEMS levadura 2 (4):. 539 - . 550 DOI : 10.1111/j.1567-1364.2002.tb00121.x . PMID 12702270 .
  40. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:485-60.
  41. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996;226:339-45.
  42. Bagchi N, Fawcett DM. Role of sodium ion in active transport of iodide by cultured thyroid cells. Biochim Biophys Acta. 1973 Aug 22;318(2):235–251
  43. Carrasco N. Iodide transport in the thyroid gland . Biochim Biophys Acta 1993; 1154:65-82.
  44. Eskyari S, Loo DD, Dai G, Levy O, Wright EM, y Carrasco N Thyroid Na+/I- symporter. Mechanism, stoichiometry, and specificity. J Biol Chem 1997; 272: 27230- 27238.
  45. Filetti S, Bidart J-M, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/ iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999;141:443–457.
  46. Brown-Grant K Extra thyroidal iodide concentrating mechanisms. Physiol Rev 1961; 41: 189-213
  47. De la Vieja, Dohán, Ginter et al.LA SAGA DEL TRANSPORTADOR DE YODURO (NIS): DE SU IDENTIFICACIÓN MOLECULAR A SU PAPEL CLÍNICO EN EL CÁNCER. Mensaje Bioquímico, Vol XXVI. Depto Bioquímica, Fac Me- dicina, Universidad Nacional Autónoma de México. Cd Universitaria, México, DF, MÉXICO. (2002).
  48. Schmutzler C, Winzer R, Meissner-Weigl J & Kohrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in non transformed FRTL-5 rat thyroid cells. Biochemical and Biophysical Research Communications 1997 240 832–838.
  49. Smanik PA, Ryu K-Y, Theil KS, Mazzaferri EL & Jhiang SM. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997 138 3555–3558.
  50. Arturi F, Russo D, Schlumberger M, DuVillard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG & Filetti S. Iodide symporter gene expression in human thyroid tumors. Journal of Clinical Endocrinology and Metabolism 1998 83 2493 – 2496.
  51. Schmutzler C & Kohrle J. Implications of the molecular characterization of the sodium–iodide symporter (NIS). Experi- mental and Clinical Endocrinology and Diabetes 1998 106 (Suppl 3) S1–S9.
  52. Min JJ, Chung JK, Lee Y, Jeong J, Lee D, Jang J, et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imag 2001;28:639-45.
  53. Mian C, Barollo S, Pennelli G, Pavan N, Rugge M. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol 2008;68:108-16.
  54. Park HJ, Kim JY, Park KY, Gong G, Hong SJ, Ahn IM. Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroidcarcinoma. Thyroid. 2000;10:211–217. –
  55. Arturi F, Russo D, Giuffrida D, Schlumberger M, Filetti S. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol 2000;143:623-7.